Indian pharma companies have been struggling to maintain margins because of strong headwinds. Due to increased competition, pharma companies are experiencing price erosion in the market, resulting in sluggish growth. While price erosion is not the only issue at hand, China’s lockdown that caused supply chain disruption, the rise in raw material prices, and the Russia-Ukraine war have raised packaging costs.
F&O Talk: Nifty loses key supports amid tariff turmoil: what’s next? Preeti Chabra weighs in
President Trump’s tariff announcement triggered volatility across global markets, with Indian indices falling 2.6%. Analyst Preeti K. Chabra shares insights on Nifty, Bank Nifty, and